These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 31594101)
21. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy - meta-analysis. Xu J; Li J; Chen J; Liu ZJ Adv Clin Exp Med; 2015; 24(2):331-40. PubMed ID: 25931368 [TBL] [Abstract][Full Text] [Related]
22. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. Wang JH; Hu TH; Chen CH; Hung CH; Yen YH; Chang KC; Lu SN Kaohsiung J Med Sci; 2019 Nov; 35(11):708-714. PubMed ID: 31430035 [TBL] [Abstract][Full Text] [Related]
23. Management of chronic hepatitis B in severe liver disease. Fung J; Lai CL; Yuen MF World J Gastroenterol; 2014 Nov; 20(43):16053-61. PubMed ID: 25473157 [TBL] [Abstract][Full Text] [Related]
24. Impact of hepatitis B therapy on the long-term outcome of liver disease. Liaw YF Liver Int; 2011 Jan; 31 Suppl 1():117-21. PubMed ID: 21205148 [TBL] [Abstract][Full Text] [Related]
25. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102 [TBL] [Abstract][Full Text] [Related]
26. Oncogenic viruses and hepatocellular carcinoma. Ben Ari Z; Weitzman E; Safran M Clin Liver Dis; 2015 May; 19(2):341-60. PubMed ID: 25921667 [TBL] [Abstract][Full Text] [Related]
27. [Effect of nucleos(t)ide analog antiviral treatment on the occurrence of hepatitis B virus-associated hepatocellular carcinoma]. Xu M; Lan Y; Li Y Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):312-4. PubMed ID: 25199211 [No Abstract] [Full Text] [Related]
28. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Yang T; Lu JH; Zhai J; Lin C; Yang GS; Zhao RH; Shen F; Wu MC Eur J Surg Oncol; 2012 Aug; 38(8):683-91. PubMed ID: 22621971 [TBL] [Abstract][Full Text] [Related]
29. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention]. Han C; Dou XG Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951 [TBL] [Abstract][Full Text] [Related]
30. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. Chen VL; Yeh ML; Le AK; Jun M; Saeed WK; Yang JD; Huang CF; Lee HY; Tsai PC; Lee MH; Giama N; Kim NG; Nguyen PP; Dang H; Ali HA; Zhang N; Huang JF; Dai CY; Chuang WL; Roberts LR; Jun DW; Lim YS; Yu ML; Nguyen MH Aliment Pharmacol Ther; 2018 Jul; 48(1):44-54. PubMed ID: 29797518 [TBL] [Abstract][Full Text] [Related]
31. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? Wang CC; Kao JH Expert Opin Pharmacother; 2016; 17(7):911-9. PubMed ID: 26831361 [TBL] [Abstract][Full Text] [Related]
32. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination. Kim MN; Han KH; Ahn SH Semin Oncol; 2015 Apr; 42(2):316-28. PubMed ID: 25843736 [TBL] [Abstract][Full Text] [Related]
33. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Kim MN; Hwang SG; Kim BK; Park JY; Kim DY; Han KH; Kim SU; Ahn SH Gut Liver; 2019 Mar; 13(2):197-205. PubMed ID: 30602075 [TBL] [Abstract][Full Text] [Related]
34. Treatment of HBV related cirrhosis. van Bömmel F; Berg T Liver Int; 2013 Feb; 33 Suppl 1():176-81. PubMed ID: 23286862 [TBL] [Abstract][Full Text] [Related]
35. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. Song BG; Sinn DH; Chi S; Kim K; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1447-1452. PubMed ID: 30063482 [TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432 [TBL] [Abstract][Full Text] [Related]
37. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455 [TBL] [Abstract][Full Text] [Related]